Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 18/20 | 0.62 |
| ▸ | ABL1 | P00519 | 1/20 | 0.49 |
| ▸ | BCR | P11274 | 1/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.49 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.49 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9898579 | 0.89 | FAAH (0.77) | FAAH | |
| SCHEMBL4295390 | 0.88 | FAAH (0.81) | FAAH | |
| SCHEMBL9925714 | 0.86 | FAAH (0.77) | FAAHTP53CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9899538 | 0.84 | FAAH (0.79) | FAAH | |
| SCHEMBL9925777 | 0.84 | FAAH (0.66) | FAAH | |
| SCHEMBL9900647 | 0.83 | FAAH (0.81) | FAAH | |
| SCHEMBL9900727 | 0.83 | FAAH (0.63) | FAAH | |
| SCHEMBL9899680 | 0.80 | FAAH (0.75) | FAAH | |
| SCHEMBL9899245 | 0.80 | FAAH (0.77) | FAAH | |
| SCHEMBL9899554 | 0.80 | FAAH (0.53) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8906914-B2 | Ethylene diamine modulators of fatty acid hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-09 | — | — | US | claimed |
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-14 | — | — | US | claimed |
| US-8906914-B2 | Ethylene diamine modulators of fatty acid hydrolase | JANSSEN PHARMACEUTICA NV (BE) | 2014-12-09 | — | — | US | disclosed |
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2012-06-14 | — | — | US | disclosed |
| WO-2011022348-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID AMIDE HYDROLASE | JANSSEN PHARMACEUTICA NV (BE) | 2011-02-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120149696-A1 | ETHYLENE DIAMINE MODULATORS OF FATTY ACID HYDROLASE | FAAH, FAAH2, APEH | FAAH 1/4885ABL1 4278/4885BCR 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.